GeneDx’s Post

The CRISPR/Cas9 mechanism has opened doors for new, viable ways of treating severe diseases. The intensive research on guide RNAs (gRNAs), Cas mRNA and proteins, and their delivery mechanisms has increased specificity, safety, and efficiency tremendously in the last several years. These research efforts have also led to an increase in the variety and complexity of CRISPR-based therapies. To streamline analytics and realize the full potential of life-changing therapies, it's crucial to have a strong partner by your side. Explore how intuitive, informative, and flexible analytical solutions can help you break through characterization boundaries of CRISPR/Cas9 therapies. Let us help you in your journey towards making a difference. #CRISPR #Cas9 #Therapies #Analytics #LifeChanging

The key is to combine #clinicaldata with #omicsdata! #Precisionmedicine aims to enhance patient outcomes by combining molecular information (epigenomics, genomics, transcriptomics, etc.) and health related data from patients. It focuses on individualized disease prevention, diagnosis, and treatment. #healthcare #medicine #multiomics #omics #translationalmedicine #translationalprecisionmedicine #translationalresearch

Access to genomic medicine is pivotal in unraveling the complexities of #RUNX1FPD, a rare disease that may be more prevalent in families than currently recognized. By referring your patients with #RUNX1 variants to this groundbreaking The National Institutes of Health RUNX1 Clinical Research Study, you're not just contributing to our collective understanding; you're also opening doors for individuals to receive accurate diagnoses and potentially life-saving information in the future: https://lnkd.in/gA7mYpWS #raredisease #genomicmedicine #patientcare

In this blog, Martin Roessner, Corporate Vice President of Biostatistics at Parexel, highlights the need for sensitivity in Alzheimer’s trial design, considering the diminishing ability of patients to communicate as the disease progresses. "Nowhere is the patient-first ethos more critical than in developing treatments for Alzheimer’s disease." Explore the use of genomic and biomarker classification, digital technologies, and alternate trial designs to improve efficacy and reduce patient burden. Read the full article here: https://lnkd.in/ezgw73ji #Alzheimers #PatientsFirst #ParexelBiotech

In this blog, Martin Roessner, Corporate Vice President of Biostatistics at Parexel, highlights the need for sensitivity in Alzheimer’s trial design, considering the diminishing ability of patients to communicate as the disease progresses. "Nowhere is the patient-first ethos more critical than in developing treatments for Alzheimer’s disease." Explore the use of genomic and biomarker classification, digital technologies, and alternate trial designs to improve efficacy and reduce patient burden. Read the full article here: https://lnkd.in/enva4fp8 #Alzheimers #PatientsFirst #ParexelBiotech

Are you a clinician involved in requesting genomic testing? Find out what's important to know and do to maximise the chance that a diagnosis can be found by colleagues analysing the results: https://buff.ly/3W8uh3B #VariantFiltering #GenomicTesting

In this blog, Martin Roessner, Corporate Vice President of Biostatistics at Parexel, highlights the need for sensitivity in Alzheimer’s trial design, considering the diminishing ability of patients to communicate as the disease progresses. "Nowhere is the patient-first ethos more critical than in developing treatments for Alzheimer’s disease." Explore the use of genomic and biomarker classification, digital technologies, and alternate trial designs to improve efficacy and reduce patient burden. Read the full article here: https://lnkd.in/gSwaFbex #Alzheimers #PatientsFirst #ParexelBiotech

In this blog, Martin Roessner, Corporate Vice President of Biostatistics at Parexel, highlights the need for sensitivity in Alzheimer’s trial design, considering the diminishing ability of patients to communicate as the disease progresses. "Nowhere is the patient-first ethos more critical than in developing treatments for Alzheimer’s disease." Explore the use of genomic and biomarker classification, digital technologies, and alternate trial designs to improve efficacy and reduce patient burden. Read the full article here: https://lnkd.in/gE9s_KWg #Alzheimers #PatientsFirst #ParexelBiotech

In this blog, Martin Roessner, Corporate Vice President of Biostatistics at Parexel, highlights the need for sensitivity in Alzheimer’s trial design, considering the diminishing ability of patients to communicate as the disease progresses. "Nowhere is the patient-first ethos more critical than in developing treatments for Alzheimer’s disease." Explore the use of genomic and biomarker classification, digital technologies, and alternate trial designs to improve efficacy and reduce patient burden. Read the full article here: https://lnkd.in/dnAbEYYY #Alzheimers #PatientsFirst #ParexelBiotech

In this blog, Martin Roessner, Corporate Vice President of Biostatistics at Parexel, highlights the need for sensitivity in Alzheimer’s trial design, considering the diminishing ability of patients to communicate as the disease progresses. "Nowhere is the patient-first ethos more critical than in developing treatments for Alzheimer’s disease." Explore the use of genomic and biomarker classification, digital technologies, and alternate trial designs to improve efficacy and reduce patient burden. Read the full article here: https://lnkd.in/eKzwV8Sx #Alzheimers #PatientsFirst #ParexelBiotech